Stockscreener 앱 받기
11.58
2.93%
-0.35
시장 영업 전:
11.35
-0.23
-1.99%
전일 마감가:
$11.93
열려 있는:
$12.4
하루 거래량:
1.10M
Relative Volume:
19.61
시가총액:
$1.48B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.00
$12.40
1주일 범위
$11.00
$13.95
52주 변동 폭
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
11.58 | 1.52B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc 주식(GENB)의 최신 뉴스
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com Nigeria
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - marketscreener.com
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Generate:Biomedicines Rings the Opening Bell - Nasdaq
Generate Biomedicines secures $400m IPO in flurry of February listings - Yahoo Finance
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - The Malaysian Reserve
Generate Biomedicines Announces IPO Terms for $400 Million Raise - Intellectia AI
GENB Stock Price, News & Analysis - Stock Titan
Drug developer Generate Biomedicines raises $400 million in US IPO - marketscreener.com
Generate caps a strong month for biotech IPOs with $400M offering - BioPharma Dive
AI biotech Generate Biomedicines raises $400M in IPO - Axios
Generate Biomedicines prices IPO at $16 per share - Investing.com
Lo sviluppatore di farmaci Generate Biomedicines raccoglie 400 milioni di dollari nell'IPO statunitense - TradingView
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO - Bloomberg.com
GENBGenerate Biomedicines Latest Stock News & Market Updates - Stock Titan
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (GENB) Stock Forecast & Price Target - Investing.com
Generate Biomedicines IPO Closing Market Cap Trading Odds & Predictions - Polymarket
Generate Biomedicines Inc Consensus Estimates (GENB) - Investing.com South Africa
AI pharmaceutical company Generate Biomedicines (GENB.US) sets IPO price at $16 per share, to be listed on Nasdaq tonight - Bitget
Preview: Generate Biomedicines, Inc Set To IPO Tomorrow - Benzinga
Generate Biomedicines Inc (GENB) 재무 분석
Generate Biomedicines Inc (GENB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):